| Elainemd, Inc | |
|
466 Foothill Blvd # 181 La Canada CA 91011-3518 | |
| (818) 279-8199 | |
| Not Available |
| Full Name | Elainemd, Inc |
|---|---|
| Speciality | Clinic/Center |
| Location | 466 Foothill Blvd, La Canada, California |
| Authorized Official Name and Position | Elaine Y Chu (MEDICAL DIRECTOR) |
| Authorized Official Contact | 8182798199 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Elainemd, Inc 466 Foothill Blvd # 181 La Canada CA 91011-3518 Ph: (818) 279-8199 | Elainemd, Inc 466 Foothill Blvd # 181 La Canada CA 91011-3518 Ph: (818) 279-8199 |
| NPI Number | 1255519104 |
|---|---|
| Provider Enumeration Date | 02/03/2008 |
| Last Update Date | 08/17/2022 |
| Medicare PECOS PAC ID | 6800944604 |
|---|---|
| Medicare Enrollment ID | O20090505000503 |
News Archive
Halozyme Therapeutics, Inc. today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. Halozyme and Baxter are finalizing the materials for a meeting with the U.S. Food and Drug Administration to seek concurrence with the reintroduction strategy.
In heart failure patients with diabetes and/or chronic kidney disease, a new, non-steroidal mineralocorticoid receptor antagonist (MRA) called finerenone was no more effective than the currently approved MRA eplerenone in reducing the heart failure biomarker N-terminal pro-B-type natriuretic peptide [NT-proBNP].
I was disappointed to read your letter regarding the media report published in Reuters yesterday as well as your assertion that WellPoint "deliberately works to deny coverage for women diagnosed with breast cancer." Both your statement and Mr. Waas' piece are inaccurate and grossly misrepresent WellPoint's efforts to help prevent, detect, and treat the 1 in 8 of our 34 million members nationwide affected by breast cancer.
Cancer cells have an enormous need for oxygen and nutrients. Therefore, growing tumors rely on the simultaneous growth of capillaries, the fine branching blood vessels that form a supply network for them.
New safety data from a study of patients with advanced Parkinson's disease five years after gene transfer-mediated delivery of the neuroprotective factor neurturin directly to patients' brains reveal no serious adverse events related to the treatment.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255519104 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | A47836 (California) | Primary |
| Provider Name | Elaine Y Chu |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1194892919 PECOS PAC ID: 8729136528 Enrollment ID: I20090505000494 |
News Archive
Halozyme Therapeutics, Inc. today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. Halozyme and Baxter are finalizing the materials for a meeting with the U.S. Food and Drug Administration to seek concurrence with the reintroduction strategy.
In heart failure patients with diabetes and/or chronic kidney disease, a new, non-steroidal mineralocorticoid receptor antagonist (MRA) called finerenone was no more effective than the currently approved MRA eplerenone in reducing the heart failure biomarker N-terminal pro-B-type natriuretic peptide [NT-proBNP].
I was disappointed to read your letter regarding the media report published in Reuters yesterday as well as your assertion that WellPoint "deliberately works to deny coverage for women diagnosed with breast cancer." Both your statement and Mr. Waas' piece are inaccurate and grossly misrepresent WellPoint's efforts to help prevent, detect, and treat the 1 in 8 of our 34 million members nationwide affected by breast cancer.
Cancer cells have an enormous need for oxygen and nutrients. Therefore, growing tumors rely on the simultaneous growth of capillaries, the fine branching blood vessels that form a supply network for them.
New safety data from a study of patients with advanced Parkinson's disease five years after gene transfer-mediated delivery of the neuroprotective factor neurturin directly to patients' brains reveal no serious adverse events related to the treatment.
› Verified 3 days ago
News Archive
Halozyme Therapeutics, Inc. today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. Halozyme and Baxter are finalizing the materials for a meeting with the U.S. Food and Drug Administration to seek concurrence with the reintroduction strategy.
In heart failure patients with diabetes and/or chronic kidney disease, a new, non-steroidal mineralocorticoid receptor antagonist (MRA) called finerenone was no more effective than the currently approved MRA eplerenone in reducing the heart failure biomarker N-terminal pro-B-type natriuretic peptide [NT-proBNP].
I was disappointed to read your letter regarding the media report published in Reuters yesterday as well as your assertion that WellPoint "deliberately works to deny coverage for women diagnosed with breast cancer." Both your statement and Mr. Waas' piece are inaccurate and grossly misrepresent WellPoint's efforts to help prevent, detect, and treat the 1 in 8 of our 34 million members nationwide affected by breast cancer.
Cancer cells have an enormous need for oxygen and nutrients. Therefore, growing tumors rely on the simultaneous growth of capillaries, the fine branching blood vessels that form a supply network for them.
New safety data from a study of patients with advanced Parkinson's disease five years after gene transfer-mediated delivery of the neuroprotective factor neurturin directly to patients' brains reveal no serious adverse events related to the treatment.
› Verified 3 days ago
Adventist Health Physicians Network Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1975 Verdugo Blvd Ste A, La Canada, CA 91011 Phone: 818-249-9454 Fax: 818-249-9420 | |
Richard A. Compton, D.o., A Professional Corporation Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1109 Foothill Blvd, La Canada, CA 91011 Phone: 818-643-7128 Fax: 818-514-2383 | |
Healthylife Mg Corp Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 245 Berkshire Ave, La Canada, CA 91011 Phone: 818-361-5437 | |
Optimum Medical Group North Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2258 Foothill Blvd Ste 200, La Canada, CA 91011 Phone: 954-675-3257 | |
Foothill Plaza Medical Group Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1751 Foothill Blvd, 3, La Canada, CA 91011 Phone: 818-790-9990 | |
William F. Schubert, M.d. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1407 Foothill Blvd, La Canada, CA 91011 Phone: 818-790-1121 Fax: 818-790-1122 |